| Title | Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines |
| Authors | Zhu, Yufan Lu, Yingyin Zhou, Cail Tong, Ganglin Gao, Manman Zhan, Yan Wang, Yan Liang, Ran Li, Yawei Gao, Tianjiao Wang, Li Zhang, Muyun Cheng, Jin Gong, Jun Wang, Jimin Zhang, Wei Qi, Junhua Cui, Miao Zhu, Longchao Xiao, Fenglian Zhu, Linyu Xu, Yunsheng Zheng, Zhihua Zhou, Zhiyu Cheng, Zhengjiang Hong, Peng |
| Affiliation | Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Div Lab Med, Lab Clin Immunol,Affiliated Hosp, Xiangyang, Hubei, Peoples R China Sun Yat Sen Univ, Affiliated Hosp 7, Ctr Kidney Dis, Dept Nephrol, Shenzhen, Guangdong, Peoples R China City Univ Hong Kong, Shenzhen Res Inst, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China Peking Univ, Dept Oncol, Shenzhen Hosp, Shenzhen, Guangdong, Peoples R China Sun Yat Sen Univ, Affiliated Hosp 7, Dept Orthoped Surg, Innovat Platform Regenerat & Repair Spinal Cord &, Shenzhen, Guangdong, Peoples R China Shenzhen Univ, Shenzhen Peoples Hosp 2, Inst Translat Med, Dept Sport Med,Affiliated Hosp 1, Shenzhen, Guangdong, Peoples R China Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Rehabil Med, Affiliated Hosp, Xiangyang, Hubei, Peoples R China Fujian Med Univ, Dept Obstet & Gynecol, Nanping Hosp 1, Nanping, Fujian, Peoples R China Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Res Affairs, Affiliated Hosp, Xiangyang, Hubei, Peoples R China Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Orthoped Surg, Affiliated Hosp, Xiangyang, Hubei, Peoples R China Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Tradit Chinese Med, Affiliated Hosp, Xiangyang, Hubei, Peoples R China Sun Yat Sen Univ, Affiliated Hosp 7, Dept Res Affairs, Shenzhen, Guangdong, Peoples R China Sun Yat Sen Univ, Affiliated Hosp 7, Dept Lab Med, Shenzhen, Guangdong, Peoples R China Mt Sinai St Lukes Roosevelt Hosp Ctr, Dept Pathol, New York, NY 10025 USA Shenzhen Bay Lab, Inst Infect Dis, Shenzhen, Guangdong, Peoples R China Nanfang Coll, Guangzhou, Guangdong, Peoples R China Sun Yat Sen Univ, Affiliated Hosp 7, Dept Dermatol, Shenzhen, Guangdong, Peoples R China Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou, Guangdong, Peoples R China New York Harbor Healthcare Syst, Div Res & Dev, US Dept Vet Affairs, Brooklyn, NY 11209 USA SUNY Downstate Hlth Sci Univ, Dept Cell Biol, Brooklyn, NY 11203 USA |
| Keywords | ANTIBODY |
| Issue Date | 12-Aug-2022 |
| Publisher | MED |
| Abstract | Background: Emerging evidence suggests heterologous prime-boost COVID-19 vaccination as a superior strategy than homologous sched-ules. Animal experiments and clinical observations have shown enhanced antibody response against influenza variants after heterolo-gous vaccination; however, whether the inoculation order of COVID-19 vaccines in a prime-boost schedule affects antibody response against SARS-CoV-2 variants is not clear.Methods: We conducted immunological analyses in a cohort of health care workers (n = 486) recently vaccinated by three types of inactivated COVID-19 vaccines under homologous or heterologous prime-boost schedules. Antibody response against ancestral SARS-CoV-2 (Wuhan -Hu-1) was assessed by total antibody measurements, surrogate virus neutralization tests, and pseudovirus neutralization assays (PNA). Furthermore, serum neutralization activity against SARS-CoV-2 variants of concern was also measured by PNA.Findings: We observed strongest serum neutralization activity against the widely circulating SARS-CoV-2 variant B.1.617.2 among recipients of heterologous BBIBP-CorV/CoronaVac and WIBP-CorV/CoronaVac. In contrast, recipients of CoronaVac/BBIBP-CorV and CoronaVac/ WIBP-CorV showed significantly lower B.1.617.2 neutralization titers than recipients of reverse schedules. Laboratory tests revealed that neutralizing activity against common variants but not the ancestral SARS-CoV-2 was associated with the inoculation order of heterologous prime-boost vaccines. Multivariable regression analyses confirmed this association after adjusting for known confounders.Conclusions: Our data provide clinical evidence of inoculation order -dependent expansion of neutralizing breadth against SARS-CoV-2 in recipients of heterologous prime-boost vaccination and call for further studies into its underlying mechanism.Funding: National Key R&D Program of China, National Development and Re-form Commission of China, National Natural Science Founda-tion of China, Shenzhen Science and Technology Innovation Commis-sion, and US Department of Veterans Affairs. |
| URI | http://hdl.handle.net/20.500.11897/654129 |
| ISSN | 2666-6340 |
| DOI | 10.1016/j.medj.2022.05.003 |
| Indexed | ESCI |
| Appears in Collections: | 深圳医院 |
